ArriVent BioPharma Inc (NASDAQ: AVBP) is a clinical-stage biopharmaceutical company developing targeted oncology therapies, with its pipeline focused on non-small cell lung cancer and gastrointestinal cancers. The company has generated no product revenue since inception and funds operations entirely through capital raises. Key pipeline assets include firmonertinib, targeting NSCLC mutations, and ARR-217, targeting gastrointestinal cancers. ArriVent reported a net loss of $166.3 million for the year ended December 31, 2025, and $80.5 million for the year ended December 31, 2024, with an accumulated deficit of $404.6 million as of December 31, 2025. Substantially all losses stem from in-licensing intellectual property, clinical development expenses, and general and administrative costs. The company conducts clinical operations across the United States and China, relying on contract research organizations and third-party manufacturers. No products have received regulatory approval as of the filing date of March 5, 2026.

Revenue model

ArriVent has no approved products and has generated no revenue since inception. Operations are funded through equity capital. Future revenue, if any, would depend on regulatory approval and commercialization of product candidates.

Products and services

Firmonertinib: clinical-stage EGFR-targeted therapy for non-small cell lung cancer (NSCLC). ARR-217: clinical-stage therapy targeting gastrointestinal cancers. Both candidates are in development with no regulatory approvals as of the 10-K filed March 5, 2026.

Customers and end markets

End markets are oncology patients with NSCLC mutations and gastrointestinal cancers. No commercial customers exist as of December 31, 2025. Future customers would include hospital systems, oncology clinics, and payers under potential Medicare Part B and Part D reimbursement frameworks.

Value-chain role

ArriVent licenses intellectual property, sponsors clinical trials through contract research organizations, and relies on third-party manufacturers for drug supply. It does not own manufacturing facilities. Clinical data transfer operations span the United States and China.

Geographic exposure

Clinical development operations in the United States and China. Data transfers between the two countries are subject to U.S. DOJ Bulk Transfer Rule (effective October 2025), China's Data Security Law (effective September 2021), and related cross-border data regulations.

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations Peers: 4D Molecular Therapeutics Inc 89bio, Inc. Immunome Inc Dianthus Therapeutics Inc Praxis Precision Medicines Inc Scholar Rock Holding Corp CARGO Therapeutics, Inc.